Interferonopathies

Ex vivo study
#Arthritis #Interferonopathies #Lupus #Protein inhibitor

UK company identifies potential new treatment for lupus

Domainex has revealed human ex vivo data indicating that DMXD-011 could be effective in treating interferonopathies such as lupus, Sjögren’s syndrome, and scleroderma. The drug candidate is an inhibitor of protein kinases TBK1 and IKK-epsilon, which previous studies suggest should be highly-effective in the treatment of inflammatory diseases. The efficacy of DMXD-011… Read More

#News